NIPBL Therapeutics Foundation
Scientific Briefing
NIPBL & Cornelia de Lange Syndrome
A molecular and clinical primer — the gene and its cohesin biology, the CdLS phenotype spectrum, and the syndrome-specific growth and developmental profiles.
The gene: NIPBL
NIPBL (Nipped-B-like, historically termed delangin) is the principal gene of Cornelia de Lange syndrome. Located at chromosome 5p13.2, it encodes the cohesin-loading factor — the protein that deposits the cohesin ring complex onto DNA. Pathogenic NIPBL variants account for the majority of molecularly confirmed CdLS and, as a group, the most clinically recognizable (“classic”) presentations.
Cohesin is a ring-shaped, multi-subunit complex (SMC1A, SMC3, the RAD21 kleisin, and a STAG subunit) that topologically embraces DNA. NIPBL, acting as an obligate heterodimer with MAU2 (the metazoan orthologs of yeast Scc2–Scc4 and Drosophila Nipped-B), recognizes loading sites, opens the ring, and stimulates cohesin's ATPase to drive deposition. Beyond holding sister chromatids together for faithful chromosome segregation, NIPBL-loaded cohesin powers DNA loop extrusion — the active reeling of chromatin into loops that juxtapose enhancers with promoters and partition the genome into topologically associating domains (TADs).
This loop-extrusion role makes cohesin a master regulator of developmental gene expression, and it is why CdLS is classified as a cohesinopathy rather than a simple structural-chromosome condition. Critically, NIPBL is dosage-sensitive: even modest reductions in expression — reported as low as ~15% in some contexts — have been associated with CdLS-like developmental effects. Because the deficit is one of quantity in an otherwise-functional pathway, the condition is conceptually tractable.
Heterozygous Nipbl+/− mice carry only a ~25–30% drop in transcript — the intact allele partially compensates — yet reproduce the syndrome (small size, craniofacial anomalies, microbrachycephaly, heart defects, hearing loss, low body fat, delayed bone maturation) with no sister-chromatid-cohesion defect. Genome-wide, reduced NIPBL lowers cohesin binding and preferentially downregulates cohesin-target genes by weakening promoter–enhancer contact; over half of all dysregulated transcripts are direct cohesin targets. Gene activation, not chromosome cohesion, is the dosage-sensitive function — grounding CdLS as a diagnosis of transcriptional regulation. (Kawauchi et al., PLoS Genet 2009; Newkirk et al., Clin Epigenetics 2017)
The CdLS phenotype
CdLS is a multisystem developmental diagnosis with a recognizable gestalt: distinctive craniofacial features (synophrys and arched brows, long smooth philtrum, thin downturned upper lip, long lashes), growth restriction, microcephaly, upper-limb reduction differences, gastrointestinal disease, sensory deficits, and variable neurodevelopmental and behavioral involvement. Severity is a continuum — from classic, severe presentations to mild forms that can escape clinical recognition.
The table below summarizes the cardinal features by system. No single sign is obligatory; diagnosis rests on the overall pattern, supported where possible by molecular confirmation of a variant in NIPBL or another cohesin-pathway gene. Variant class is an important severity correlate — truncating and frameshift variants cluster with the classic, more severe end of the spectrum, while missense and in-frame variants generally retain partial function and trend milder — though phenotype is not fully predictable from genotype alone.
Gastrointestinal disease — gastroesophageal reflux, esophagitis, and gastric dysmotility — is among the most significant and treatable sources of morbidity in CdLS, and a frequent driver of feeding difficulty and poor weight gain. Reflux is often silent, so a high index of suspicion and proactive surveillance are recommended; severe oral aversion or failure to thrive may warrant gastrostomy. Because GI burden contributes directly to the growth profile in §3, feeding and growth are best interpreted together. (First international consensus statement, Kline et al. 2018)
Growth profile
Children with CdLS grow slowly and often proportionately — though gastrointestinal disease (reflux, dysmotility, oral aversion) can drive a disproportionate weight deficit. Plotted against standard population charts they fall far below the curves and are frequently mislabeled “failure to thrive.” The appropriate reference is the set of CdLS-specific growth charts (Kline et al., 1993), which describe the syndrome's own distribution for height, weight, and head circumference.
Head circumference in CdLS likewise runs persistently below typical norms throughout childhood, paralleling the weight and height curves — in the syndrome this is the expected trajectory, not an isolated red flag, and is best tracked on the CdLS-specific head-circumference chart rather than population norms.
Developmental profile
Development in CdLS follows the typical sequence but on a delayed and widely variable timeline, with expressive language characteristically the most affected domain. Kline et al. (1993) quantified milestone attainment across a CdLS cohort; the windows below span first-reported age to 95% completion, with the median (50%) marked.
Because comprehension and intent in CdLS frequently outpace speech output, early augmentative and alternative communication (AAC) — alongside speech, occupational, and physical therapy — is the standard-of-care scaffold while expressive language develops on its delayed trajectory. Hearing should be assessed early and repeatedly, since undetected hearing loss can compound the expressive-language delay.
Accelerate NIPBL research into the clinic.
Because CdLS stems from dysregulation of one essential protein, it is uniquely targetable. We fund the research to get there — and support the families living with NIPBL-related diagnosis today.
Further reading & resources
Curated entry points for clinicians, researchers, and families — from plain-language overviews to curated gene–phenotype catalogs and the international clinical consensus.